CorMedix Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update
CorMedix Inc. (CRMD)
NASDAQ:AMEX Investor Relations:
cormedix.com
Company Research
Source: GlobeNewswire
BERKELEY HEIGHTS, N.J., Nov. 14, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced financial results for the third quarter and nine months ended September 30, 2019 and provided an update on recent business developments. Recent Corporate Highlights: Positive responses received from the FDA regarding the Company’s pre-New Drug Application, or pre-NDA, meeting questions relating to the preparation of the NDA. The FDA agreed that Neutrolin is eligible for priority review, setting a review period goal of 6 months rather than the standard review period of 10 months. The FDA also agreed that the Neutrolin NDA submission is eligible for rolling review and that the Company’s proposed submission plan is reasonable. The FDA further agreed that it is appropriate to submit a request for approval of Neu
Show less
Read more
Impact Snapshot
Event Time:
CRMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRMD alerts
High impacting CorMedix Inc. news events
Weekly update
A roundup of the hottest topics
CRMD
News
- CorMedix Inc. Announces CMS Grants TDAPA to DefenCath [Yahoo! Finance]Yahoo! Finance
- CorMedix Inc. Announces CMS Grants TDAPA to DefenCathGlobeNewswire
- CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath® (Taurolidine and Heparin) [Yahoo! Finance]Yahoo! Finance
- CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath® (Taurolidine and Heparin)GlobeNewswire
- Wall Street Analysts Predict a 146.21% Upside in CorMedix (CRMD): Here's What You Should Know [Yahoo! Finance]Yahoo! Finance
CRMD
Earnings
- 3/12/24 - Miss
CRMD
Sec Filings
- 3/20/24 - Form 4
- 3/20/24 - Form 4
- 3/20/24 - Form 4
- CRMD's page on the SEC website